What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?
Elisa Tassinari,Matteo Rosellini,Andrea Marchetti,Veronica Mollica,Francesco Massari
DOI: https://doi.org/10.1080/17425255.2024.2314059
2024-02-06
Expert Opinion on Drug Metabolism & Toxicology
Abstract:KEYWORDS: Immunotherapy has recently revolutionized the treatment scenario of several solid malignancies. In fact, the use of immune-checkpoint inhibitors (ICIs) is constantly spreading across different histologies, disease settings, and lines of therapy, with plenty of pivotal clinical trials assessing their undiscussed role in everyday clinical practice [ Citation 1 ]. Furthermore, ICIs are usually well tolerated, with a low impact on a patient's quality of life (QoL), if compared to non-ICIs treatment regimens [ Citation 2 ]. Besides impressive clinical efficacy and acceptable manageability, a unique and probably underestimated spectrum of adverse reactions has been reported, with toxicities that may sometimes lead to treatment withdrawal and, uncommonly, to fulminant and fatal events. Indeed, the break of immune balance induced by ICIs and the subsequent reduction of T-cells tolerance leads to a novel class of side effects, known as immune-related adverse events (irAEs), which may involve all organs and systems, resulting in a wide spectrum of possible clinical presentations [ Citation 3 ]. irAEs' incidence seems to be underreported and affected by, among others, compound used (for instance, anti-CTLA-4 showed a less tolerable safety profile than anti-PD-1/PD-L1), combination strategies (such as dual ICIs or concomitant use of chemotherapy or tyrosine-kinase inhibitors – TKIs), tumor type, and individual risk factors (i.e. age, gender, comorbidity, diet, and microbiota) [ Citation 3 ]. They generally occur as grade 1 or 2 (according to the Common Terminology Criteria for Adverse Events – CTCAE), with approximately 10–20% of patients experiencing grade 3 or 4 [ Citation 3 ]. The mainstay of irAEs' management – that lays its roots on early identification – is based on temporary or permanent discontinuation, corticosteroids administration, and, in special cases, immunomodulatory agents [ Citation 4 ].
pharmacology & pharmacy,biochemistry & molecular biology,toxicology